Fore Biotherapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
49
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$183M
- Investors
-
22
Fore Biotherapeutics General Information
Description
Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and gnomically defined cancer patients. The company's clinical-stage drug development aids in recapitulating naturally occurring mutations in vitro and tests their effect on signaling pathway activity and their response to different compounds, enabling biopharma companies to receive support in identifying new target mutations and expanding subgroups of cancer patients to respond to existing therapies.
Contact Information
Website
www.fore.bioCorporate Office
- 3675 Market Street
- Suite 200
- Philadelphia, PA 19104
- United States
Corporate Office
- 3675 Market Street
- Suite 200
- Philadelphia, PA 19104
- United States
Fore Biotherapeutics Timeline
Fore Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series D) | 08-Jul-2026 | $183M | Completed | Clinical Trials - Phase 2 | ||
| 6. Secondary Transaction - Private | 01-Jul-2023 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series C) | 21-Sep-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Merger/Acquisition | 17-Dec-2018 | Cancelled | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B) | 30-Apr-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 31-Jan-2017 | $900K | $12.5M | Completed | Clinical Trials - Phase 1 | |
| 1. Later Stage VC (Series A) | 22-Jun-2016 | $12.5M | $12.5M | Completed | Clinical Trials - Phase 1 |
Fore Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B | 54,869 | $0.000010 | 8% | $319.75 | $319.75 | 1x | $319.75 | 0.18% |
| Series A | 6,706 | $0.000010 | 8% | $298 | $298 | 1x | $298 | 0.02% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Fore Biotherapeutics Comparisons
Industry
Financing
Details
Fore Biotherapeutics Competitors (48)
One of Fore Biotherapeutics’s 48 competitors is Aegle Therapeutics, a Venture Capital-Backed company based in Woburn, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aegle Therapeutics | Venture Capital-Backed | Woburn, MA | ||||
| Cardiff Oncology | Formerly Angel backed | San Diego, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| NextCure | Formerly VC-backed | Beltsville, MD | ||||
| ArriVent Biopharma | Formerly VC-backed | Newtown Square, PA |
Fore Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Fore Biotherapeutics Patents
Fore Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026188088-A1 | Method of treating neurodegenerative langerhans cell histiocytosis | Pending | 06-Mar-2025 |
Fore Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Fore Biotherapeutics Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Axil | Corporation | Minority | ||
| LG Technology Ventures | Corporate Venture Capital | Minority | ||
| Medicxi Ventures (UK) | Venture Capital | Minority | ||
| Primer Ventures | Venture Capital | Minority | ||
| Samsung Securities | Corporation | Minority |
Fore Biotherapeutics FAQs
-
When was Fore Biotherapeutics founded?
Fore Biotherapeutics was founded in 2011.
-
Where is Fore Biotherapeutics headquartered?
Fore Biotherapeutics is headquartered in Philadelphia, PA.
-
What is the size of Fore Biotherapeutics?
Fore Biotherapeutics has 49 total employees.
-
What industry is Fore Biotherapeutics in?
Fore Biotherapeutics’s primary industry is Drug Discovery.
-
Is Fore Biotherapeutics a private or public company?
Fore Biotherapeutics is a Private company.
-
What is Fore Biotherapeutics’s current revenue?
The current revenue for Fore Biotherapeutics is .
-
How much funding has Fore Biotherapeutics raised over time?
Fore Biotherapeutics has raised $258M.
-
Who are Fore Biotherapeutics’s investors?
Axil, LG Technology Ventures, Medicxi Ventures (UK), Primer Ventures, and Samsung Securities are 5 of 22 investors who have invested in Fore Biotherapeutics.
-
Who are Fore Biotherapeutics’s competitors?
Aegle Therapeutics, Cardiff Oncology, Ayala Pharmaceuticals, NextCure, and ArriVent Biopharma are some of the 48 competitors of Fore Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
